Loading
Life sciences · Journal article
Frontiers in Oncology · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Trastuzumab deruxtecan (T-DXd) has transformed the management of Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer (mBC). However, its role in visceral crisis (VC) remains unclear due to exclusion from clinical trials and limited real-world evidence. We report the case of a 40-year-old woman with HER2-positive mBC who after first-line therapy developed severe hepatic dysfunction due to liver progression, consistent with hepatic VC. Following multidisciplinary discussion and informed consent, T-DXd as second line therapy was initiated at a reduced dose (3.2 mg/kg), leading to rapid normalization of liver function, symptom relief, and radiologic response. Subsequent stepwise escalation to the standard dose (5.4 mg/kg) was well tolerated, with durable disease control and no additional toxicity. Our findings, in this otherwise underexplored setting, together with similar experiences reported in the literature, support T-DXd as a safe and effective therapeutic option for HER2-positive mBC complicated by hepatic VC. Further evidence is needed to better inform clinical practice in terms of optimal, tailored dose-escalation strategies in this context.